ReviewMolecular immunology2009
Recent developments in low molecular weight complement inhibitors.
Review in Molecular immunology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 107 citations in OpenAlex.
- Complement protein concentrations and activity in human cervical mucus.bioRxiv : the preprint server for biology · 2026Article
- Interaction Effects Between Tongue-Rolling Behavior and Chronic Stress on Plasma Immune-Inflammatory Indicators, Milk Protein Composition, and Milk Proteome in Dairy Cows.Veterinary sciences · 2026Article
- Complement C3 in panvascular disease: a central integrator of immune signaling and vascular remodeling.Clinical science (London, England : 1979) · 2025Review
- Complement system activation: bridging physiology, pathophysiology, and therapy.Intensive care medicine · 2024Review
- The Role of Innate Immunity in Osteoarthritis and the Connotation of "Immune-joint" Axis: A Narrative Review.Combinatorial chemistry & high throughput screening · 2024Review
- Characterization and functional analysis of hybrid pearl gentian grouper (Fish and shellfish immunology reports · 2021Article
- Review
- Effect of Aerobic and Anaerobic Exercise on the Complement System of Proteins in Healthy Young Males.Journal of clinical medicine · 2020Article
- Molecular Mechanisms of Premature Aging in Hemodialysis: The Complex Interplay Between Innate and Adaptive Immune Dysfunction.International journal of molecular sciences · 2020Review
- Significance of Complement System in Ischemic Stroke: A Comprehensive Review.Aging and disease · 2019Review
- New tricks for an ancient system: Physiological and pathological roles of complement in the CNS.Molecular immunology · 2018Review
- Orthosteric and allosteric action of the C5a receptor antagonists.Nature structural & molecular biology · 2018Article
- The Complement System in Dialysis: A Forgotten Story?Frontiers in immunology · 2018Review
- Genome Mining of the Marine ActinomyceteFrontiers in microbiology · 2018Article
- Identification of C3b-Binding Small-Molecule Complement Inhibitors Using Cheminformatics.Journal of immunology (Baltimore, Md. : 1950) · 2017Article
- The relative merits of therapies being developed to tackle inappropriate ('self'-directed) complement activation.Auto- immunity highlights · 2016Article
- Anti-Complementary Components of Helicteres angustifolia.Molecules (Basel, Switzerland) · 2016Article
- From orphan drugs to adopted therapies: Advancing C3-targeted intervention to the clinical stage.Immunobiology · 2016Review
- New milestones ahead in complement-targeted therapy.Seminars in immunology · 2016Review
- Complementing the inflammasome.Immunology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
As a key part of the innate immune system, complement plays an important role not only in defending against invading pathogens but also in many other biological processes. Inappropriate or excessive activation of complement has been linked to many autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer. A wide array of low molecular weight complement inhibitors has been developed to target various components of the complement cascade. Their efficacy has been demonstrated in numerous in vitro and in vivo experiments. Though none of these inhibitors has reached the market so far, some of them have entered clinical trials and displayed promising results. This review provides a brief overview of the currently developed low molecular weight complement inhibitors, including short peptides and synthetic small molecules, with an emphasis on those targeting components C1 and C3, and the anaphylatoxin receptors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.